Holders — by stockHoldings — by fund
Atlas Venture Life Science Advisors, LLC
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001917529
$881.3M
disclosed book value
7
positions
37.1%
largest position share
Positions, as of 2026-06-30
top 7 of 7 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | KYMRKymera Therapeutics, Inc. | 2.8M | $326.5M | 37.1% |
| 2 | DYNDyne Therapeutics, Inc. | 6.8M | $151.0M | 17.1% |
| 3 | SIONSionna Therapeutics, Inc. | 3.0M | $131.8M | 15% |
| 4 | KLRAKailera Therapeutics, Inc. | 5.2M | $113.9M | 12.9% |
| 5 | IRONDisc Medicine, Inc. | 1.5M | $110.7M | 12.6% |
| 6 | QTTBQ32 Bio, Inc. | 2.7M | $34.6M | 3.9% |
| 7 | KRROKorro Bio, Inc. | 962,884 | $12.7M | 1.4% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.